~~CLAIMS~~

~~1. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant.~~

~~2. The rapidly disintegrating preparation according to claim 1, wherein the granules comprising a medicament further contains a binder.~~

~~3. The rapidly disintegrating preparation according to claim 1, wherein the granules comprising a medicament further contains a masking agent.~~

~~4. The rapidly disintegrating preparation according to claim 1, wherein the granules comprising a medicament further contains a solubilizer.~~

~~5. The preparation according to any of claims 1 – 4, which is for oral-mucosal absorption.~~

~~6. The preparation according to claim 5, wherein the medicament is (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide.~~

~~7. The preparation according to claim 5 or 6, which is a tablet.~~

~~8. A method of producing a rapidly disintegrating preparation, comprising a step of producing granules comprising a medicament, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules, and a step of mixing the coated granules with a disintegrant and molding the mixture.~~

9. A preparation for oral-mucosal absorption comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide as a medicament; which shows a higher ratio of the medicament in an unchanged form and a metabolite of the medicament after transfer into blood than that by oral administration.

10. A preparation for oral-mucosal absorption comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide as a medicament; which shows a higher ratio of the medicament in an unchanged form and a metabolite of the medicament after transfer into blood than that by oral administration, and a disintegration time of not more than 30 sec.

11. A preparation for oral-mucosal absorption comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide as a medicament; which shows a higher ratio of the medicament in an unchanged form and a metabolite of the medicament after transfer into blood than that by oral administration, a disintegration time of not more than 30 sec, and absolute hardness of not less than 1.0 N/mm^2.

12. A preparation for oral-mucosal absorption comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide and a masking agent; which shows not less than about 10-fold improved bioavailability of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, as compared to that by oral administration.

13. A preparation for oral-mucosal absorption comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide and a masking agent; which shows not

~~less than about 10-fold improved bioavailability of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, as compared to that by oral administration, and a disintegration time of not more than 30 sec.~~

~~14. A preparation for oral-mucosal absorption comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide and a masking agent; which shows not less than about 10-fold improved bioavailability of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, as compared to that by oral administration, a disintegration time of not more than 30 sec, and absolute hardness of not less than 1.0 N/mm^2.~~

~~15. A preparation for oral-mucosal absorption comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, sugar or sugar alcohol, and a disintegrant; which shows not less than about 10-fold improved bioavailability of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, as compared to that by oral administration, and a disintegration time of not more than 30 sec.~~

~~16. A preparation for oral-mucosal absorption comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, sugar or sugar alcohol, and a disintegrant; which shows not less than about 10-fold improved bioavailability of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, as compared to that by oral administration, a disintegration time of not more than 30 sec, and absolute hardness of not less than 1.0 N/mm^2.~~

~~17. The preparation according to any of claims 9 - 16, which is a tablet.~~

CLAIMS

~~18. The preparation according to claim 9 or 12, which is in the form of a film, troche, solution, suspension, freeze-dried preparation, chewing-gum or spray.~~

~~19~~1. Use of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide in the manufacture of a medicament for ~~preventing and/or treating~~the prophylaxis and/or treatment of a bipolar disorder, wherein said (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide is to be administered oral-mucosally to a human.

~~20~~2. The use according to claim ~~19~~1, wherein the oral-mucosal administration is sublingual administration or buccal administration.

~~21~~3. The use according to claim ~~19~~1, wherein (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide is to be administered in 0.05 - 1.0 mg per day.

~~22~~4. The use according to claim ~~19~~1, wherein the bipolar disorder is bipolar disorder I.

~~23~~5. The use according to claim ~~19~~1, wherein the prophylaxis and/or treatment of a bipolar disorder is a treatment of a depression symptom associated with the bipolar disorder or maintenance of a remission phase of the bipolar disorder.

~~24. A drug for the prophylaxis and/or treatment of a bipolar disorder, which comprises, as an active ingredient, (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide to be oral-mucosally administered to a human.~~

~~25. The drug according to claim 24, wherein the oral-mucosal administration is sublingual administration or buccal administration.~~

26. The drug according to claim 24, wherein (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide is administered in 0.05 - 1.0 mg per day.

27. The drug according to claim 24, wherein the bipolar disorder is bipolar disorder I.

28. The drug according to claim 24, wherein the prophylaxis and/or treatment of a bipolar disorder is a treatment of a depression symptom associated with the bipolar disorder or maintenance of a remission phase of the bipolar disorder.

29. (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide for the prophylaxis and/or treatment of a bipolar disorder by oral mucosal administration to a human.

30. The (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide according to claim 29, wherein the oral mucosal administration is sublingual administration or buccal administration.

31. The (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide according to claim 29, which is administered in 0.05 - 1.0 mg per day.

32. The (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide according to claim 29, wherein the bipolar disorder is bipolar disorder I.

33. The (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide according to claim 29, wherein the prophylaxis and/or treatment of the bipolar disorder is a treatment of a depression symptom associated with the bipolar disorder or maintenance of a remission phase of the bipolar disorder.

6. The use according to claim 1, wherein the medicament is a rapidly disintegrating preparation comprising granules comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide coated with a coating layer containing sugar or sugar alcohol; and a disintegrant.

7. The use according to claim 6, wherein the granules comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide further contains a binder.

8. The use according to claim 6, wherein the granules comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide further contains a masking agent.

9. The use according to claim 6, wherein the granules comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide further contains a solubilizer.

10. The use according to claim 1 or 6, wherein the medicament is a tablet.

11. A method of producing a rapidly disintegrating preparation for oral-mucosal absorption for the prophylaxis and/or treatment of a bipolar disorder, comprising a step of producing granules comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules, and
a step of mixing the coated granules with a disintegrant and molding the mixture.

12. The use according to claim 1, wherein the medicament is a preparation comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide; which medicament shows a higher ratio of an unchanged form and a metabolite of (S)-N-[2-(1,6,7,8-tetrahydro-

2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide after transfer into blood than that by oral administration.

13. The use according to claim 1, wherein the medicament is a preparation comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide; which medicament shows a higher ratio of an unchanged form and a metabolite of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide after transfer into blood than that by oral administration, and a disintegration time of not more than 30 sec.

14. The use according to claim 1, wherein the medicament is a preparation comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide; which medicament shows a higher ratio of an unchanged form and a metabolite of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide after transfer into blood than that by oral administration, a disintegration time of not more than 30 sec, and absolute hardness of not less than 1.0 N/mm^2.

15. The use according to claim 1, wherein the medicament is a preparation comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide and a masking agent; which medicament shows not less than about 10-fold improved bioavailability of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, as compared to that by oral administration.

16. The use according to claim 1, wherein the medicament is a preparation comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide and a masking agent; which medicament shows not less than about 10-fold improved bioavailability of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, as compared to that by oral administration, and a disintegration time of not more than 30 sec.

17. The use according to claim 1, wherein the medicament is a preparation comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide and a masking agent; which medicament shows not less than about 10-fold improved bioavailability of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, as compared to that by oral administration, a disintegration time of not more than 30 sec, and absolute hardness of not less than 1.0 N/mm^2.

18. The use according to claim 1, wherein the medicament is a preparation comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, sugar or sugar alcohol, and a disintegrant; which medicament shows not less than about 10-fold improved bioavailability of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, as compared to that by oral administration, and a disintegration time of not more than 30 sec.

19. The use according to claim 1, wherein the medicament is a preparation comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, sugar or sugar alcohol, and a disintegrant; which medicament shows not less than about 10-fold improved bioavailability of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, as compared to that by oral administration, a disintegration time of not more than 30 sec, and absolute hardness of not less than 1.0 N/mm^2.

20. The use according to any of claims 12-19, wherein the preparation is a tablet.

21. The use according to claim 12 or 15, wherein the preparation is in the form of a film, troche, solution, suspension, freeze-dried preparation, chewing gum or spray.